Core Viewpoint - The company has approved a share repurchase plan, intending to buy back a portion of its A-shares within a specified budget and timeframe [1]. Summary by Sections Share Repurchase Plan - The company plans to repurchase A-shares with a total fund amounting to no less than RMB 100 million and no more than RMB 150 million, with a maximum repurchase price of RMB 35 per share [1]. - The repurchase period will last for 12 months from the date of the annual general meeting where the plan was approved [1]. Initial Repurchase Details - On May 28, 2025, the company executed its first repurchase of 626,000 A-shares, representing 0.06% of the total share capital [1]. - The highest transaction price was RMB 19.97 per share, while the lowest was RMB 19.83 per share, with a total transaction amount of RMB 12,462,976 (excluding transaction fees) [1]. Compliance with Regulations - The company strictly adhered to the relevant regulations during the repurchase process, ensuring compliance with the Shenzhen Stock Exchange's guidelines [2][3]. - The company did not repurchase shares during periods that could significantly impact the trading price of its securities [2].

证券代码：000581 200581 证券简称：威孚高科 苏威孚 B 公告编号：2025-041 无锡威孚高科技集团股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 无锡威孚高科技集团股份有限公司（以下简称"公司"）于2025年4月16日及2025 年5月9日分别召开第十一届董事会第六次会议及2024年年度股东大会，审议通过了《关 于回购公司部分A股股份方案的议案》。公司将以集中竞价交易方式回购公司部分A股 股份，本次回购资金总额不低于人民币10,000万元（含）且不超过人民币15,000万元（含）； 回购股份（A股）价格不超过人民币35元/股（含），回购期限自2024年年度股东大会 审议通过回购股份方案之日起12个月内，具体回购股份的数量以回购期满时实际回购 股份的数量为准 。 具体内容详见公司于 2025 年 5 月 16 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的《关于回购公司部分A股股份的回购报告书》。 1 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》（以下简称"《回 ...

Core Viewpoint - The company reported mixed financial results for 2024 and Q1 2025, with revenue growth stagnating and net profit declining significantly, indicating challenges in traditional business segments while exploring new growth areas in smart electric and non-automotive sectors [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 11.167 billion yuan, a year-on-year increase of 0.67%, while net profit decreased by 9.68% to 1.660 billion yuan [1]. - For Q1 2025, revenue was 2.834 billion yuan, down 2.38%, and net profit fell sharply by 35.46% to 354 million yuan [1]. Business Segment Analysis - The fuel injection system, a core traditional business, saw revenue decline by 8.52% to 4.645 billion yuan due to reduced demand for traditional fuel vehicles amid the electric vehicle trend [2]. - The automotive after-treatment system reported a revenue increase of 1.99% to 3.477 billion yuan, with an improved gross margin from 12.52% to 15.11% [2]. - The intake system benefited from the hybrid market, achieving a significant revenue growth of 43.93% to 0.954 billion yuan, although its gross margin decreased from 22.42% to 19.52% [2]. Profitability Trends - The company's gross margin for 2024 was 18.18%, a slight increase of 0.67 percentage points, while the net margin decreased by 1.87 percentage points to 15.38% [3]. - In Q1 2025, the gross margin was 17.67%, down 0.86 percentage points, and the net margin fell by 6.91 percentage points to 12.92% [3]. Strategic Initiatives - The company is actively expanding into smart electric and non-automotive sectors, establishing a joint venture with Baolong Technology to develop full-active suspension motor hydraulic pump business [3]. - A strategic cooperation agreement was signed with Bosch China to enhance collaboration in automotive intelligence, hydrogen energy, and humanoid robotics, among other areas [4]. Investment Outlook - In the short term, the company’s traditional business remains stable, while new smart electric initiatives are expected to enter a phase of order release, leading to a potential upward trend in overall performance [5]. - For the medium to long term, the company aims to increase external collaborations and diversify its business ecosystem, which may open new growth opportunities [5].

Investment Rating - The report assigns an "Accumulate-A" rating for the company, marking its first coverage [1][9]. Core Views - The company is experiencing short-term profit pressure but is accelerating the construction of a new ecosystem in the smart electric and industrial sectors [2][4]. - The traditional core business of automotive fuel injection systems is facing a decline due to the shift towards electric vehicles, while the intake system business is benefiting from the rapid growth in hybrid vehicle sales [5][6]. - The company is actively expanding into smart electric components and non-automotive sectors, aiming to build a diversified business ecosystem for sustainable growth [6][8]. Financial Performance Summary - In 2024, the company achieved a revenue of 11.167 billion yuan, a year-on-year increase of 0.67%, while the net profit attributable to shareholders was 1.660 billion yuan, a decrease of 9.68% [4]. - For Q1 2025, the company reported a revenue of 2.834 billion yuan, down 2.38% year-on-year, and a net profit of 354 million yuan, down 35.46% [4]. - The gross margin for 2024 was 18.18%, a slight increase of 0.67 percentage points year-on-year, while the net margin was 15.38%, a decrease of 1.87 percentage points [6]. Business Segment Performance - The automotive fuel injection system segment generated revenue of 4.645 billion yuan, down 8.52% year-on-year, while the automotive after-treatment system saw revenue of 3.477 billion yuan, up 1.99% [5]. - The intake system business experienced significant growth, with revenue reaching 954 million yuan, a year-on-year increase of 43.93% [5]. Future Outlook - The company is expected to see revenue growth in the coming years, with projected revenues of 11.854 billion yuan, 12.848 billion yuan, and 14.085 billion yuan for 2025, 2026, and 2027, respectively [9][11]. - The net profit attributable to shareholders is forecasted to be 1.410 billion yuan, 1.460 billion yuan, and 1.824 billion yuan for the same years [9][11].

Investment Rating - The report assigns an "Accumulate-A" rating for the company, marking its first coverage [1][8]. Core Views - The company is experiencing short-term profit pressure but is accelerating the construction of a new ecosystem in the smart electric and industrial sectors [2][4]. - The traditional core business of automotive fuel injection systems has seen a decline in revenue due to the shift towards electric vehicles, while the intake system business has benefited from the rapid growth in hybrid vehicle sales [4][5]. - The company is actively expanding into smart electric and non-automotive sectors, aiming to build a diversified business ecosystem for sustainable growth [5][7]. Financial Performance Summary - In 2024, the company achieved a revenue of 11.167 billion yuan, a year-on-year increase of 0.67%, while the net profit attributable to shareholders was 1.660 billion yuan, a decrease of 9.68% [3][4]. - For Q1 2025, the company reported a revenue of 2.834 billion yuan, down 2.38% year-on-year, and a net profit of 354 million yuan, down 35.46% year-on-year [3][4]. - The gross margin for 2024 was 18.18%, an increase of 0.67 percentage points year-on-year, while the net margin was 15.38%, a decrease of 1.87 percentage points year-on-year [5][10]. Business Segment Analysis - The automotive fuel injection system segment generated revenue of 4.645 billion yuan in 2024, a decline of 8.52% year-on-year, while the automotive after-treatment system saw revenue of 3.477 billion yuan, a growth of 1.99% [4]. - The intake system business experienced significant growth, with revenue reaching 954 million yuan, a substantial increase of 43.93% year-on-year, despite a decline in gross margin from 22.42% to 19.52% [4][5]. Future Outlook - The company is expected to see revenue growth in the coming years, with projected revenues of 11.854 billion yuan in 2025, 12.848 billion yuan in 2026, and 14.085 billion yuan in 2027 [8][10]. - The net profit attributable to shareholders is forecasted to be 1.410 billion yuan in 2025, 1.460 billion yuan in 2026, and 1.824 billion yuan in 2027 [8][10]. - The company is focusing on external collaborations and expanding into non-automotive sectors, which is anticipated to open new growth opportunities [5][8].

Core Viewpoint - Weifu High-Tech has established a joint venture to enhance its business in the fully active suspension system sector, leveraging its technological advantages and distribution channels [1][2]. Group 1: Joint Venture Details - Weifu High-Tech's subsidiary, Weifu Jinning, will invest 220 million yuan (approximately 32.1 million USD) for a 55% stake in the newly formed Weifu Baolong Technology Co., Ltd., while Baolong Technology will invest 180 million yuan (approximately 26 million USD) for a 45% stake [1]. - The joint venture aims to synergize Weifu Jinning's fully active suspension motor hydraulic pump technology with Baolong Technology's suspension system distribution advantages to maximize commercial benefits for both shareholders [2]. Group 2: Company Background and Financials - Weifu High-Tech, originally established in 1958, focuses on the research, production, and sales of core automotive components, with its automotive parts business generating 11.01 billion yuan (approximately 1.58 billion USD) in revenue in 2024, accounting for 98.6% of total revenue [2]. - The company has significantly increased its R&D investment, with expenditures of 582 million yuan, 668 million yuan, and 690 million yuan from 2022 to 2024, totaling 1.94 billion yuan (approximately 280 million USD) over three years [2]. - Despite the increase in R&D spending, Weifu High-Tech faces challenges due to intensified market competition and declining investment income, with revenues of 11.17 billion yuan and 2.834 billion yuan in 2024 and Q1 2025, reflecting year-on-year changes of 0.67% and -2.38% respectively [3].

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Group 1 - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [3] - ST Zhongdi has decided to abandon the commercial opportunity for the Jiageng Ke Yi City land project, with the controlling shareholder planning to develop the project instead [4] - Xichang Electric Power expects a reduction of approximately 5.4 million yuan in net profit for 2025 due to adjustments in the time-of-use electricity pricing mechanism [5] Group 2 - Sanfu New Materials intends to invest 620 million yuan in a project for high-safety dry electrode battery key materials and high-frequency electronic information composite materials [6] - Weifu High-Tech's subsidiary plans to establish a joint venture with Baolong Technology to expand the active suspension motor hydraulic pump business [7] - Yulong Co., Ltd. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [8] Group 3 - Chen'an Technology's shareholder is transferring 6.27% of the company's shares to Hefei Guotou, aiming to introduce strategic investors [9] - Huamao Technology is planning to acquire a 100% stake in Fuchuang Youyue, with stock trading suspended for up to 10 trading days [11] - Baolong Technology's subsidiary will collaborate with Weifu High-Tech's subsidiary to develop core components for the active suspension system [12] Group 4 - Zhongnong Lihua intends to acquire at least 50% of Taizhou Agricultural Supplies, enhancing its product and service range [13] - Weiling Co., Ltd.'s subsidiary has successfully acquired 74.3% of Jiayu Mining for 220 million yuan, focusing on expanding into the non-ferrous metal resource sector [14][15] - Hengshi Technology's subsidiary has been approved for public transfer of shares on the New Third Board [16] Group 5 - Xiang Teng New Materials plans to acquire an additional 12.5% stake in its subsidiary Shanghai Shangda for 25.3 million yuan [17] - ST Texin has extended its employee stock ownership plan by 12 months, reflecting confidence in the company's long-term development [18] - Baili Electric has issued a risk warning regarding its stock price increase, indicating no significant changes in fundamentals [19] Group 6 - Hu Silicon Industry plans to acquire minority stakes in three semiconductor companies for approximately 7.04 billion yuan [20][21] - Demais plans to change its controlling shareholder, leading to a temporary suspension of stock trading [22] - FAW Fuwei has received a notice from a well-known new energy brand for a project expected to generate 1.06 billion yuan in total sales over its lifecycle [23] Group 7 - Hangyang Co. plans to establish a subsidiary for a large modular cryogenic equipment manufacturing project with an estimated investment of 557 million yuan [24] - Jiewate intends to acquire 40.89% of Tianyi Hexin for 319 million yuan, enhancing its product line in the signal chain category [25] - Dingxin Communications has elected a new chairman following the resignation of the previous chairman [26][27] Group 8 - Aofei Entertainment plans to invest 10 million yuan in a partnership to indirectly invest in AI robotics company Xuan Yuan Technology [28] - Huaxi Energy's controlling shareholder has been detained, but the company states that operations remain normal [29] - Yihe Jiaye will change its stock name to "Ruimaite" starting May 21 [30] Group 9 - Zhongjin Environment will change its name to "Southern Pump Industry" effective May 21 [31] - Hong Sifang's subsidiary plans to invest approximately 1.49 billion yuan in a new chemical materials and fertilizers industrial park [32] - Buchang Pharmaceutical's subsidiary has signed a research agreement for MF59 adjuvant with a pharmaceutical company [33] Group 10 - Hongjing Technology has signed a service contract worth 597 million yuan for a smart computing project [34] - Zhuojin Co. has won a bid for a soil remediation project worth 67.68 million yuan [35] - Xinjiang Jiaojian has been awarded a contract for a highway project valued at 451 million yuan [36] Group 11 - China National Materials Energy's subsidiary has signed a contract for an EPC project in Uzbekistan worth approximately 1.252 billion yuan [37] - Ruixin Microelectronics' shareholder plans to reduce its stake by up to 2% [38] - Shanghai Yizhong's shareholder also plans to reduce its stake by up to 2% [39] Group 12 - Sanyou Medical's controlling shareholder plans to reduce its stake by up to 1.44% [40] - Hangdian Co.'s controlling shareholder plans to reduce its stake by up to 1.93% [41] - Shangwei New Materials' shareholder plans to reduce its stake by up to 3% [42] Group 13 - Mingchen Health plans to repurchase shares worth between 30 million and 50 million yuan [43] - Jiuhua Tourism plans to raise up to 500 million yuan through a private placement for various projects [44] - Yuegui Co. plans to raise up to 900 million yuan for several projects [46]

Group 1 - Zhaoyi Innovation plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [3] - ST Zhongdi has decided to abandon the commercial opportunity for the Jiageng Science and Art City land project, which has an area of 108,600 square meters and a starting price of 2.067 billion yuan [4] - Xichang Electric Power expects a reduction of approximately 5.4 million yuan in net profit for 2025 due to adjustments in the time-of-use electricity pricing mechanism [5] Group 2 - Sanfu New Technology plans to invest 620 million yuan in a project for high-safety dry electrode battery key materials and high-frequency electronic information composite materials, with production expected to start in June 2025 [6] - Weifu High-Tech's subsidiary will establish a joint venture with Baolong Technology to expand the business of fully active suspension motor hydraulic pumps, with a registered capital of 400 million yuan [7] - Yulong Co., Ltd. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [8] Group 3 - Chensan Technology's shareholder Shanghai Ruiwei will transfer 14.58 million shares, representing 6.27% of the company, to Hefei Guotou, with the transfer price set at 17.7 yuan per share [10] - Huamao Technology is planning to acquire a 100% stake in Fuchuang Youyue, currently holding 42.16% of the company, with stock trading suspended for up to 10 days [11] - Baolong Technology's subsidiary will partner with Weifu High-Tech's subsidiary to develop and mass-produce core components for fully active suspension systems [12] Group 4 - Buchang Pharmaceutical's subsidiary has signed a commissioned research agreement with Fubicheng Pharmaceutical for the MF59 emulsion adjuvant [14] - Hongjing Technology has signed a service contract worth 597 million yuan for a smart computing project, with a duration of five years [15] - Zhuojin Co., Ltd. has won a bid for a soil remediation project worth 67.68 million yuan, with an expected share of approximately 59.9 million yuan [16] - Xinjiang Jiaojian has been awarded a contract for the G3013 line Ucha to Kangsou highway project, with a bid amount of 451 million yuan [17] Group 5 - Mingchen Health plans to repurchase shares worth between 30 million and 50 million yuan for employee stock ownership plans, with a maximum repurchase price of 23 yuan per share [19]

Group 1 - Hongjing Technology signed a service contract for an intelligent computing project with a total amount of 597 million yuan, valid for 5 years [1] - Weifu High-Tech's subsidiary invested 220 million yuan to establish a joint venture with Shanghai Baolong Automotive Technology [2] - Zhongshan Public received approval for the registration of short-term financing bonds amounting to 2 billion yuan and medium-term notes of 3 billion yuan [3] Group 2 - Lianhua Technology established a venture capital fund with a total commitment of 200 million yuan, contributing 100 million yuan as a limited partner [4] - Changan Technology's shareholder signed an agreement to transfer 6.27% of the company's shares to Hefei State Capital Venture Investment [6] - Hangzhou Garden announced a cash dividend of 0.5 yuan per 10 shares, totaling 6.62 million yuan [8] Group 3 - Huamao Technology plans to acquire 100% equity of Fuchuang Youyue, leading to a temporary suspension of its stock [9] - Zhuojin Co. won a bid for a soil remediation project in Hefei with a contract value of 67.68 million yuan [10] - Shanghai Pharmaceuticals received FDA approval for two drugs, enhancing its product portfolio [10] Group 4 - Fuxing Pharmaceutical's senior vice president resigned for personal reasons [12] - Baolong Technology's subsidiary plans to invest 180 million yuan in a joint venture [13] - ST Zhongdi intends to utilize surplus funds from a project company, with a maximum of 106 million yuan [14] Group 5 - Nanchao Food reported a significant decline in net profit for April, down 82.14% year-on-year [16] - Changshan Pharmaceutical received a drug registration certificate in Belarus for a new product [18] - Nanshan Aluminum established a wholly-owned subsidiary for photovoltaic energy projects with an investment of 5 million yuan [20] Group 6 - Bozhong Precision announced the resignation of a director and deputy general manager [22] - Xinjiang Jiaojian won a bid for a highway construction project valued at 451 million yuan [23] - Guangzhou Restaurant declared a cash dividend of 0.48 yuan per share, totaling 273 million yuan [25] Group 7 - Weili Medical's subsidiary obtained a medical device operating license, allowing it to engage in wholesale activities [27] - New Australia Co. announced a cash dividend of 0.3 yuan per share, totaling 219 million yuan [28] - Lianhua Technology's subsidiary entered the new third board innovation layer [29] Group 8 - Huaxi Energy's chairman resigned due to personal reasons [31] - Yipin Hong plans to use up to 500 million yuan of idle funds for cash management [33] - Shouhua Gas intends to purchase bauxite resources through market means [34] Group 9 - Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, valued at approximately 805 million USD [34] - Wanrun New Energy signed a supply contract with CATL for lithium iron phosphate products, with a total supply of about 1.32 million tons [35] - Weili plans to transfer 100% equity of a subsidiary to Chengfa Environment for 100 million yuan [36] Group 10 - Zhenlei Technology's subsidiary received government subsidies of 2.21 million yuan, positively impacting profits [38] - Weir shares plan to change their name to "Haowei Group" to reflect strategic direction [39] - YTO Express reported a revenue increase of 16.32% in April, totaling 5.755 billion yuan [39]